Potential benefits associated with DPP-4 inhibitors include lower risk of hypoglycemia, neutral effect on weight, renoprotective effects, and lowering of BP
An intervention that is beneficial for one subset of the population may be ineffective or even harmful in other subgroups (Hampel et al., 2020
GLP-1s, or glucagon-like peptide-1 receptor agonists, mimic a hormone naturally produced in the gut
Jan 7 2022;12(2)doi:10.3390/ani12020141
Derecho de oposicin: Tiene derecho a oponerse al tratamiento basado en un inters legtimo
Effects of glucagonlike peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers